ArticleThe pharmacogenomics journal2014
Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.
Article in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Pooled it
- Analysis of genetic and clinical factors associated with buprenorphine response.Drug and alcohol dependence · 2021Pooled it
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Nonpharmacological and pharmacological influences on opioid effects: A review of clinical research findings.The Journal of pharmacology and experimental therapeutics · 2025Review
- Biochemical Diagnosis in Substance and Non-substance Addiction.Advances in experimental medicine and biology · 2025Review
- Association ofJournal of clinical medicine · 2024Article
- A review of the existing literature on buprenorphine pharmacogenomics.The pharmacogenomics journal · 2021Review
- A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder.Journal of translational genetics and genomics · 2020Article
- Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone.Pharmacology, biochemistry, and behavior · 2019Article
- Molecular Basis of Cancer Pain Management: An Updated Review.Medicina (Kaunas, Lithuania) · 2019Review
- The importance of buprenorphine research in the opioid crisis.Molecular psychiatry · 2019Article
- Current understanding of the neurobiology of opioid use disorder: An overview.Current behavioral neuroscience reports · 2019Article
- Update on the pharmacogenomics of pain management.Pharmacogenomics and personalized medicine · 2019Review
- Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.Frontiers in psychiatry · 2019Review
- Pharmacogenetics of Opioid Use Disorder Treatment.CNS drugs · 2018Review
- Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.The American journal of drug and alcohol abuse · 2018Article
- A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.The pharmacogenomics journal · 2018Article
- Don't stress about CRF: assessing the translational failures of CRFPsychopharmacology · 2017Review
- Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.Clinical pharmacology in drug development · 2017Review
- Evaluation of methodology for the analysis of 'time-to-event' data in pharmacogenomic genome-wide association studies.Pharmacogenomics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Two commonly prescribed treatments for opioid addiction are methadone and buprenorphine. Although these drugs show some efficacy in treating opioid dependence, treatment response varies among individuals. It is likely that genetic factors have a role in determining treatment outcome. This study analyses the pharmacogenetic association of six polymorphisms in OPRD1, the gene encoding the delta-opioid receptor, on treatment outcome in 582 opioid addicted European Americans randomized to either methadone or buprenorphine/naloxone (Suboxone) over the course of a 24-week open-label clinical trial. Treatment outcome was assessed as the number of missed or opioid-positive urine drug screens over the 24 weeks. In the total sample, no single-nucleotide polymorphisms (SNPs) in OPRD1 were significantly associated with treatment outcome in either treatment arm. However, sex-specific analyses revealed two intronic SNPs (rs581111 and rs529520) that predicted treatment outcome in females treated with buprenorphine. Females with the AA or AG genotypes at rs581111 had significantly worse outcomes than those with the GG genotype when treated with buprenorphine (P=0.03, relative risk (RR)=1.67, 95% confidence interval (CI) 1.06-2.1). For rs529520, females with the AA genotype had a significantly worse outcome than those with the CC genotype when (P=0.006, RR=2.15, 95% CI 1.3-2.29). No significant associations were detected in males. These findings suggest that rs581111 and rs52920 may be useful when considering treatment options for female opioid addicts, however, confirmation in an independent sample is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.